.jpg){kind=logo}
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
PLATELETPHERESIS (LEUKOREDUCED)
Test CodePHPLTLR
Instructions
The patient must have a red wristband for checking against component container label prior to administration. I.V. must be running and consent form must be signed.
Many of the important clinical manifestations of transfusion reaction occur during the administration of the first 50-100 mL blood; therefore, the need for closest attention is during the early period of the transfusion. Temperature, pulse, and blood pressure must be taken and recorded before transfusion and then at 15 minutes after the transfusion is started and every hour during infusion.
Many of the important clinical manifestations of transfusion reaction occur during the administration of the first 50-100 mL blood; therefore, the need for closest attention is during the early period of the transfusion. Temperature, pulse, and blood pressure must be taken and recorded before transfusion and then at 15 minutes after the transfusion is started and every hour during infusion.
Specimen Stability
Room temperature
Setup Schedule
Daily, 24 hours
Clinical Significance
Patient Preparation
Patient must have a red wristband for checking against component container label prior to administration. A recent (ie, within the same 24-hour period) platelet count should be completed before platelets are ordered.
Dosage and administration: One plateletpheresis is equivalent to five- six units of random platelet concentrates. The number of platelet concentrates to be administered depends on the clinical situation in each patient. One unit of platelet pheresis usually increases the platelet count by 30,000-60,000 μL/m2 body surface. In calculating the body surface area of the pediatric patient, refer to the nomogram in Blood Component Therapy: A Physician's Handbook, 4th ed, Washington, DC, 1993, AABB. Please be aware that this expected increment will not be seen in patients experiencing rapid platelet destruction as might occur in association with DIC, sepsis, splenomegaly, or in the presence of platelet HLA antibodies. For a more definite evaluation of the efficacy of platelet transfusion , the physician is advised to evaluate the 1-hour post-transfusion increment rise according to the following formula:
pi = (pc2 - pc1) x bsa / c
where:
pi = platelet count increment
pc1 = platelet count pretransfusion
pc2 = platelet count post-transfusion
bsa = body surface area in m2
c = number of platelet concentrates transfused
It is desirable to use a 19-gauge needle or larger for administration to minimize aggregation. Do not warm platelets. Monitor platelet counts during the 48 hours following adminstration. Patient should have close clinical/nursing observation for bleeding, petechiae. The efficacy of platelet transfusion should be evaluated as stated above.
Use:
Platelet pheresis can be used for any patient needing platelet transfusions. Single-donor platelets have the advantage of providing an entire platelet transfusion for an adult from one donor, hence with a single antigenic combination and a single donor exposure. Furthermore, the donor can be selected (eg, from a patient's relatives or by HLA type).
Patient must have a red wristband for checking against component container label prior to administration. A recent (ie, within the same 24-hour period) platelet count should be completed before platelets are ordered.
Dosage and administration: One plateletpheresis is equivalent to five- six units of random platelet concentrates. The number of platelet concentrates to be administered depends on the clinical situation in each patient. One unit of platelet pheresis usually increases the platelet count by 30,000-60,000 μL/m2 body surface. In calculating the body surface area of the pediatric patient, refer to the nomogram in Blood Component Therapy: A Physician's Handbook, 4th ed, Washington, DC, 1993, AABB. Please be aware that this expected increment will not be seen in patients experiencing rapid platelet destruction as might occur in association with DIC, sepsis, splenomegaly, or in the presence of platelet HLA antibodies. For a more definite evaluation of the efficacy of platelet transfusion , the physician is advised to evaluate the 1-hour post-transfusion increment rise according to the following formula:
pi = (pc2 - pc1) x bsa / c
where:
pi = platelet count increment
pc1 = platelet count pretransfusion
pc2 = platelet count post-transfusion
bsa = body surface area in m2
c = number of platelet concentrates transfused
It is desirable to use a 19-gauge needle or larger for administration to minimize aggregation. Do not warm platelets. Monitor platelet counts during the 48 hours following adminstration. Patient should have close clinical/nursing observation for bleeding, petechiae. The efficacy of platelet transfusion should be evaluated as stated above.
Use:
Platelet pheresis can be used for any patient needing platelet transfusions. Single-donor platelets have the advantage of providing an entire platelet transfusion for an adult from one donor, hence with a single antigenic combination and a single donor exposure. Furthermore, the donor can be selected (eg, from a patient's relatives or by HLA type).
